Focus: DNA Script is a French biotechnology company specializing in enzymatic DNA synthesis, a platform technology enabling programmable, scalable production of synthetic DNA. The company operates at the infrastructure layer of synthetic biology and gene therapy manufacturing.
Profile data last refreshed 4h ago · AI intelligence enriched 2w ago
Stable — net +3 jobs in 30d
4 added, 1 removed. Backfill posture.
DNA Script represents a high-risk, high-reward platform biotech play best suited for early-career scientists seeking foundational impact in emerging synthetic biology infrastructure, with significant execution and funding risks.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Recently signed distribution agreements with major pharma (BMS) and biotech partners, indicating early commercial validation of core platform.
Help build intelligence for DNA Script
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from DNA Script's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Liqtech Surges 25% on Volatile Breakout: Is the Biotech Spark Igniting a New Trend? - Bitget
Liqtech Surges 25% on Volatile Breakout: Is the Biotech Spark Igniting a New Trend? Bitget
DNA Script signs SYNTAX distribution agreements with Gencell, BMS and Biostream - PharmaTimes
DNA Script signs SYNTAX distribution agreements with Gencell, BMS and Biostream PharmaTimes
FDA Holds Meeting with States on Importation of Lower Cost Drugs
FDA held a meeting with several states to discuss the section 804 importation program (SIP), which allows states and Indian tribes to import certain prescription drugs from Canada to significantly reduce the cost of these drugs to the American consumer.
Rare Disease Research: Future Steps To Accelerate Drug Development - Technology Networks
Rare Disease Research: Future Steps To Accelerate Drug Development Technology Networks
Drug discovery integration takes centre stage at SLAS Boston 2026 - Drug Target Review
Drug discovery integration takes centre stage at SLAS Boston 2026 Drug Target Review
Rare Disease Research: Exploring the Barriers in Drug Development - Technology Networks
Rare Disease Research: Exploring the Barriers in Drug Development Technology Networks
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 8 publications